- Home
- IMCR vs FSM Comparison
IMCR vs FSM Comparison
Compare IMCR & FSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- FSM
- Stock Information
- Founded
- IMCR 2008
- FSM 1990
- Country
- IMCR United Kingdom
- FSM Canada
- Employees
- IMCR N/A
- FSM N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- FSM Precious Metals
- Sector
- IMCR Health Care
- FSM Basic Materials
- Exchange
- IMCR Nasdaq
- FSM Nasdaq
- Market Cap
- IMCR 1.4B
- FSM 2.0B
- IPO Year
- IMCR 2021
- FSM N/A
- Fundamental
- Price
- IMCR $30.16
- FSM $6.04
- Analyst Decision
- IMCR Buy
- FSM Hold
- Analyst Count
- IMCR 12
- FSM 1
- Target Price
- IMCR $60.90
- FSM $7.00
- AVG Volume (30 Days)
- IMCR 378.9K
- FSM 15.6M
- Earning Date
- IMCR 05-07-2025
- FSM 05-07-2025
- Dividend Yield
- IMCR N/A
- FSM N/A
- EPS Growth
- IMCR N/A
- FSM N/A
- EPS
- IMCR N/A
- FSM N/A
- Revenue
- IMCR $310,202,000.00
- FSM $1,062,037,000.00
- Revenue This Year
- IMCR $20.52
- FSM N/A
- Revenue Next Year
- IMCR $8.57
- FSM N/A
- P/E Ratio
- IMCR N/A
- FSM $14.45
- Revenue Growth
- IMCR 24.36
- FSM 26.07
- 52 Week Low
- IMCR $23.15
- FSM $3.86
- 52 Week High
- IMCR $62.74
- FSM $6.78
- Technical
- Relative Strength Index (RSI)
- IMCR 59.11
- FSM 52.23
- Support Level
- IMCR $27.55
- FSM $5.81
- Resistance Level
- IMCR $30.85
- FSM $6.78
- Average True Range (ATR)
- IMCR 1.95
- FSM 0.43
- MACD
- IMCR 0.44
- FSM -0.05
- Stochastic Oscillator
- IMCR 89.02
- FSM 56.06
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.